XMP Investissements SAS invested in Hemarina SA
Mar 16, 2017 - RelSci Data Update
Investments

Background Information:
Hemarina SA operates as a biotechnology company which develops oxygen carrier for therapeutic and industrial applications. It offers organ preservation, wound healing, hemoglobin oxygen-carrier, cell culture and bioproduction and other perspective products. The company was founded by Franck Zal, Elisabeth Leize, Morgane Rousselot and Laurent Meijer on March 26, 2007 and is headquartered in Morlaix, France.
In The News:
Brest University Hospital and HEMARINA Present Positive New Advances from the Initial Clinical Trial of HEMO2life® at the American Transplant Congress in Seattle
June 6, 2018  •  Business Wire
Maurice Lesaffre is no longer serving in their board position at Hemarina SA
November 19, 2015  •  RelSci
Cécile Tharaud is no longer serving in their board position at Hemarina SA
September 18, 2015  •  RelSci
Hemarina SA operates as a biotechnology company which develops oxygen carrier for therapeutic and industrial applications. It offers organ preservation, wound healing, hemoglobin oxygen-carrier, cell culture and bioproduction and other perspective products. The company was founded by Franck Zal, Elisabeth Leize, Morgane Rousselot and Laurent Meijer on March 26, 2007 and is headquartered in Morlaix, France.
In The News:
XMP Investissements SAS invested in Ecrins Thérapeutics SAS
September 17, 2017  •  RelSci
XMP Investissements SAS invested in Telegrafik SAS
February 11, 2017  •  RelSci
XMP Investissements SAS invested in Rogervoice SAS
October 24, 2016  •  RelSci